![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
![Publish your Psychology fast and openly with F1000Research.]({"type":"image" , "src" : "/sda/110989/JournalAd-CFP-PsychologyF1000.jpg"})
![Dialogues in Clinical Neuroscience is now a fully Open Access journal]({"type":"image" , "src" : "/sda/111031/JournalAd-Announce-Neuroscience.jpg"})
![Call for Papers.]({"type":"image" , "src" : "/sda/111134/JournalAdOASubmissionCAIC.jpg"})
In this study, we examined the internal consistency of informant discrepancies in reports of youth behavior and emotional problems and their unique relations with youth, caregiver, and family characteristics. In a heterogeneous multisite clinic sample of 420 youths (ages 11–17 years), high internal consistency estimates were observed across measures of informant discrepancies. Further, latent profile analyses identified systematic patterns of discrepancies, characterized by their magnitude and direction (i.e., which informant reported greater youth problems). In addition, informant discrepancies systematically and uniquely related to informants’ own perspectives of youth mood problems, and these relations remained significant after taking into account multiple informants’ reports of informant characteristics widely known to relate to informant discrepancies. These findings call into question the prevailing view of informant discrepancies as indicative of unreliability and/or bias on the part of informants’ reports of youths’ behavior.
This work was supported, in part, by NIH R01 5MH066647 (PI: Eric Youngstrom). Special thanks to Heather Marcinick, the members of the ABACAB research team and personnel at Applewood Centers, and the families who participated in this study.
Dr. Findling receives or has received research support, acted as a consultant, and/or served on a speaker's bureau for Abbott, Addrenex, AstraZeneca, Biovail, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, KemPharm, Lilly, Lundbeck, Neuropharm, Novartis, Noven, Organon, Otsuka, Pfizer, Sanofi-Aventis, Sepracore, Shire, Solvay, Supernus Pharmaceuticals, Validus, and Wyeth.